Search

Author/Creator Barrett, Martin

2. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Issue 6 (June 2017)

Authors:
Davies, Andrew; Merli, Francesco; Mihaljević, Biljana; Mercadal, Santiago; Siritanaratkul, Noppadol; Solal-Céligny, Philippe; Boehnke, Axel; Berge, Claude; Genevray, Magali; Zharkov, Artem; Dixon, Mark; Brewster, Michael; Barrett, Martin; MacDonald, David
Journal:
Lancet
Issue:
Volume 4:Issue 6(2017)
Page Start:
e272
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies. Issue 5 (26th June 2021)

Authors:
Jamois, Candice; Gibiansky, Ekaterina; Gibiansky, Leonid; Chavanne, Clarisse; Morcos, Peter N.; McIntyre, Christine; Barrett, Martin; Lundberg, Linda; Zharkov, Artem; Boehnke, Axel; Frey, Nicolas
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 110:Issue 5(2021)
Page Start:
1261
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗